Site Search
Results
-
Independent Peer Review Panel Report: In Vitro Test Methods for...
... More work will have to be carried out to understand the types of materials that could be tested in these assays and how they would be handled (e.g., cell therapies and implants). ...
Size: 2.1MB https://ntp.niehs.nih.gov/iccvam/docs/pyrogen/prrevpanfinrpt.pdf -
TR-471: Cobalt Sulfate Heptahydrate (CASRN 10026-24-1) in F344...
... Heptahydrate, NTP TR 471 has largely stopped because of associated toxicity (gastrointestinal upset, goiter, car- diomyopathies) and the development of less hazardous therapies. ...
Size: 9.0MB https://ntp.niehs.nih.gov/sites/default/files/2023-08/tr471_508.pdf -
ICCVAM Biennial Progress Report 2022-2023
... Safety testing strategy for cell-based human cancer therapies Tags: NCI, stem cells Preclinical safety assessment for chimeric antigen receptor (CAR) T cell-based therapies is ...
Size: 995KB https://ntp.niehs.nih.gov/sites/default/files/2024-09/2022-2023_ICCVAMBienRpt_FD_508.pdf -
Monograph: Helicobacter pylori; May 2018
... or policy. 11 Many different therapies are used in the United States, but the ... OR intervention*[tiab] OR therapies[tiab] OR Therapy[tiab] OR ...
Size: 692KB https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/draftmono/hpyloridraftmonograph_508.pdf -
Monograph: Helicobacter pylori; September 2018
... Many different therapies are used in the United States, but the American College of ... OR intervention*[tiab] OR therapies[tiab] OR Therapy[tiab] OR ...
Size: 734KB https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/draftmono/hpyloridraftmonographrevised_508.pdf -
Minutes: BSC; June 21-22, 2010
... Dr. Fernandez asked if there would be any linkage to antidotes or clinical therapies related to studies. Dr. Fostel said that Summary Minutes June 21-22, 2010 NTP Board of ...
Size: 364KB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/bsc/2010/june/minutes20100622.pdf -
GMM-16: Genetically Modified Model Report on Study of Mixtures...
... Meta- bolic complications of HAART therapies include vas- cular necrosis, decreased bone ... Hematologic effects of AIDS therapies. Hematol. Oncol. Clin. North Am. 5, 229-248. Plumb, ...
Size: 5.4MB https://ntp.niehs.nih.gov/go/gmm16 -
TR-578: Ginkgo Biloba Extract (CASRN 90045-36-6) in F344/N Rats...
... cases of spontaneous bleeding associated with Ginkgo biloba extract through 2007, with one third of the cases involving concurrent use of antiplatelet or anticoagulant therapies. ...
Size: 4.1MB https://ntp.niehs.nih.gov/go/tr578 -
ICCVAM Biennial Progress Report 2020-2021
... and adoption of human MPS for testing therapies and improving disease understanding. ... to apply MPS to the development of therapies for COVID-19. Activities of the MPSCoRe ...
Size: 940KB https://ntp.niehs.nih.gov/iccvamreport/2021 -
RoC Background Document: Chlorozotocin (CZT); Nov. 18-19, 1996
... relative risk, 12.4; 95% confidence interval, 1.7- 250) among 2067 patients treated with methyl-CCNU. Only 1 case was observed among 1566 patients treated with other therapies. ...
Size: 1.6MB https://ntp.niehs.nih.gov/sites/default/files/ntp/newhomeroc/other_background/chlorozotocin1_508be.pdf
to Top